Author

S.I. Park

Institution: Levine Cancer Institute

Observed institution: Levine Cancer Institute

OpenAlex ID: A5081990481

BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON‐BULKY HODGKIN LYMPHOMA: AN UPDATE FROM a PHASE 2 CLINICAL TRIAL

2017 · S.I. Park, O. Olajide, et al. · Hematological Oncology · 7

Maintenance Rituximab Is Associated With Improved Overall Survival in Mantle Cell Lymphoma Patients Responding to Induction Therapy With Bendamustine + Rituximab (br)

2019 · B.T. Hill, J.M. Switchenko, et al. · Hematological Oncology · 5

Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy

2018 · B.A. Wilky, P. Kumthekar, et al. · Annals of Oncology · 2

Works count: 3

Citation count: 14

H-index: 2

I10-index: